KR950700734A - 코엔자임 에이-독립성 트랜스아실라제 및 혈소판 활성화인자 억제제(CoA-IT and PAF inhibitors) - Google Patents

코엔자임 에이-독립성 트랜스아실라제 및 혈소판 활성화인자 억제제(CoA-IT and PAF inhibitors)

Info

Publication number: KR950700734A
Authority: KR; South Korea
Prior art keywords: inhibitors; coenzyme; coa; paf; platelet activator
Prior art date: 1992-02-11

Application number

KR1019940702793A

Other languages

English (en)

Other versions

KR100291112B1 (ko

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-02-11

Filing date

1994-08-11

Publication date

1995-02-20

1992-02-11 Priority claimed from GB929202827A external-priority patent/GB9202827D0/en

1993-02-11 Application filed filed Critical

1995-02-20 Publication of KR950700734A publication Critical patent/KR950700734A/ko

2001-09-17 Application granted granted Critical

2001-09-17 Publication of KR100291112B1 publication Critical patent/KR100291112B1/ko

Links

101001074429 Bacillus subtilis (strain 168) Polyketide biosynthesis acyltransferase homolog PksD Proteins 0.000 title abstract 2
101000936617 Bacillus velezensis (strain DSM 23117 / BGSC 10A6 / FZB42) Polyketide biosynthesis acyltransferase homolog BaeD Proteins 0.000 title abstract 2
RGJOEKWQDUBAIZ-IBOSZNHHSA-N CoASH Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCS)O[C@H]1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-IBOSZNHHSA-N 0.000 title abstract 2
RGJOEKWQDUBAIZ-UHFFFAOYSA-N coenzime A Natural products OC1C(OP(O)(O)=O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 RGJOEKWQDUBAIZ-UHFFFAOYSA-N 0.000 title abstract 2
239000005516 coenzyme A Substances 0.000 title abstract 2
229940093530 coenzyme a Drugs 0.000 title abstract 2
KDTSHFARGAKYJN-UHFFFAOYSA-N dephosphocoenzyme A Natural products OC1C(O)C(COP(O)(=O)OP(O)(=O)OCC(C)(C)C(O)C(=O)NCCC(=O)NCCS)OC1N1C2=NC=NC(N)=C2N=C1 KDTSHFARGAKYJN-UHFFFAOYSA-N 0.000 title abstract 2
239000012190 activator Substances 0.000 title 1
239000003112 inhibitor Substances 0.000 title 1
239000003848 thrombocyte activating factor antagonist Substances 0.000 title 1
YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
108090000790 Enzymes Proteins 0.000 abstract 1
102000004190 Enzymes Human genes 0.000 abstract 1
208000026935 allergic disease Diseases 0.000 abstract 1
230000000172 allergic effect Effects 0.000 abstract 1
229940114079 arachidonic acid Drugs 0.000 abstract 1
235000021342 arachidonic acid Nutrition 0.000 abstract 1
230000000903 blocking effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002757 inflammatory effect Effects 0.000 abstract 1
230000010118 platelet activation Effects 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
- C07F9/6503—Five-membered rings
- C07F9/6506—Five-membered rings having the nitrogen atoms in positions 1 and 3

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

KR1019940702793A 1992-02-11 1993-02-11 코엔자임에이-독립성트랜스아실라제및혈소판활성화인자억제제 KR100291112B1 (ko)

Applications Claiming Priority (15)

Application Number	Priority Date	Filing Date	Title
US83404892A	1992-02-11	1992-02-11
US83387792A	1992-02-11	1992-02-11
US83388092A	1992-02-11	1992-02-11
US83387992A	1992-02-11	1992-02-11
US83385092A	1992-02-11	1992-02-11
US83387892A	1992-02-11	1992-02-11
US07/833880		1992-02-11
US07/833878		1992-02-11
US07/833877		1992-02-11
US07/833879		1992-02-11
GB9202827.3		1992-02-11
GB929202827A GB9202827D0 (en)	1992-02-11	1992-02-11	Compounds
US07/833850		1992-02-11
US07/834048		1992-02-11
PCT/US1993/001247 WO1993016674A1 (en)	1992-02-11	1993-02-11	CoA-IT AND PAF INHIBITORS

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
KR1020007011694A Division KR100365913B1 (ko)	1992-02-11	1993-11-02	코엔자임 에이-독립성 트랜스아실라제 및 혈소판활성화인자억제제

Publications (2)

Publication Number	Publication Date
KR950700734A true KR950700734A (ko)	1995-02-20
KR100291112B1 KR100291112B1 (ko)	2001-09-17

Family

ID=27562876

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
KR1019940702793A KR100291112B1 (ko)	1992-02-11	1993-02-11	코엔자임에이-독립성트랜스아실라제및혈소판활성화인자억제제
KR1020007011694A KR100365913B1 (ko)	1992-02-11	1993-11-02	코엔자임 에이-독립성 트랜스아실라제 및 혈소판활성화인자억제제

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
KR1020007011694A KR100365913B1 (ko)	1992-02-11	1993-11-02	코엔자임 에이-독립성 트랜스아실라제 및 혈소판활성화인자억제제

Country Status (14)

Country	Link
US (1)	US5648373A (ko)
EP (1)	EP0626969B1 (ko)
JP (1)	JP2001527506A (ko)
KR (2)	KR100291112B1 (ko)
AT (1)	ATE193290T1 (ko)
AU (2)	AU3664593A (ko)
CA (1)	CA2129897C (ko)
DE (1)	DE69328716T2 (ko)
DK (1)	DK0626969T3 (ko)
ES (1)	ES2149201T3 (ko)
GR (1)	GR3034040T3 (ko)
HK (1)	HK1013421A1 (ko)
PT (1)	PT626969E (ko)
WO (1)	WO1993016674A1 (ko)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0841910A4 (en) *	1995-07-25	2006-09-13	Smithkline Beecham Corp	INHIBITION OF A TRANSACYLASE INDEPENDENT OF COENZYME A (CoA) AND APOPTOSIS
US6083949A (en) *	1995-10-06	2000-07-04	Merck & Co., Inc.	Substituted imidazoles having anti-cancer and cytokine inhibitory activity
EP0956018A4 (en)	1996-08-21	2000-01-12	Smithkline Beecham Corp	IMIDAZOLE COMPOUNDS, COMPOSITIONS CONTAINING THEM AND THEIR USE
WO1999031099A1 (en) *	1997-12-17	1999-06-24	Merck & Co., Inc.	Integrin receptor antagonists
GB9904895D0 (en) *	1999-03-03	1999-04-28	Scarista Limited	Regulators of coenzyme-A-independent transacylase as psychotropic drugs
US20030096854A1 (en) *	2002-06-12	2003-05-22	Ho-Shen Lin	Substituted tricyclics
EP1506966A3 (en) *	2001-03-26	2005-09-14	Ortho-Mcneil Pharmaceutical, Inc.	Process for the preparation of tetrasubstituted imidazole derivatives and novel crystaline structures thereof
CZ20032871A3 (cs) *	2001-03-26	2004-08-18	Ortho@Mcneilápharmaceuticalźáinc	Způsob přípravy tetrasubstituovaných derivátů imidazolu a jejich nových krystalických struktur
FR2823747B1 (fr) *	2001-04-24	2003-05-23	Oreal	Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
FR2823751B1 (fr) *	2001-04-24	2003-05-23	Oreal	Nouveaux composes de la famille des 3-alkyl-(4,5 diphenyl- imidazol-1-yl) et leur utilisation comme anti-inflammatoires
MXPA03009850A (es) *	2001-04-27	2004-02-12	Bristol Myers Squibb Co	Inhibidores de bisarilimidazolil de hidrolasa de amida del acido graso.
US7358269B2 (en)	2002-05-21	2008-04-15	Allergan, Inc.	2-((2-Thioxo-2,3-dihydro-1H-imidazol-4-yl)methyl)-3,4-dihydronapthalen-1(2H)-one
US7323485B2 (en)	2002-05-21	2008-01-29	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
US7091232B2 (en) *	2002-05-21	2006-08-15	Allergan, Inc.	4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
TW200505446A (en) *	2003-01-17	2005-02-16	Fuj Isawa Pharmaceutical Co Ltd	Inhibitor of cox
EP2015638A4 (en) *	2006-04-28	2010-09-29	Redpoint Bio Corp	TRIARYL-SUBSTITUTED IMIDAZOLE DERIVATIVES AND THEIR USE AS TASTE INHIBITORS
WO2008140251A2 (en) *	2007-05-14	2008-11-20	University-Industry Cooperation Group Of Kyung Hee University	Cyclooxygenase-2 inhibitors
US11970460B1 (en)	2023-10-24	2024-04-30	King Faisal University	4-(4,5-bis(4-bromophenyl)-2-phenyl-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound
US11939298B1 (en) *	2023-10-25	2024-03-26	King Faisal University	5-(4,5-bis(4-bromophenyl)-2-(4-chlorophenyl)-1H-imidazol-1-yl)pentanoic acid as an antimicrobial compound
US11945783B1 (en)	2023-10-26	2024-04-02	King Faisal University	4-(4,5-bis(4-bromophenyl)-2-(4-methoxyphenyl)-1H-imidazol-1-yl)butanoic acid as an antimicrobial compound
US11932607B1 (en)	2023-10-27	2024-03-19	King Faisal University	4-(2,4,5-tris(4-chlorophenyl)-1H-imidazol-1-yl)benzoic acid as an antimicrobial compound

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3021338A (en) *	1956-12-05	1962-02-13	Rohm & Haas	Adducts of heterocyclic amides
CH633779A5 (de) *	1977-07-07	1982-12-31	Ciba Geigy Ag	Verfahren zur herstellung neuer vinylaether und deren verwendung zur herstellung von polymeren.
DE2823197A1 (de) *	1978-05-24	1979-11-29	Schering Ag	Neue imidazolderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
DE3228271A1 (de) *	1982-07-29	1984-02-02	A. Nattermann & Cie GmbH, 5000 Köln	Triphenylimidazolyloxyalkansaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5248689A (en) *	1989-11-06	1993-09-28	Smithkline Beecham Corporation	Substituted N-(imidazolyl)alkyl alanine derivatives
GB9019839D0 (en) *	1990-09-11	1990-10-24	Smith Kline French Lab	Compounds
US5087634A (en) *	1990-10-31	1992-02-11	G. D. Searle & Co.	N-substituted imidazol-2-one compounds for treatment of circulatory disorders
US5256695A (en) *	1991-07-24	1993-10-26	E. R. Squibb & Sons, Inc.	Acyl amidine and acyl guanidine substituted biphenyl derivatives

1993
- 1993-02-11 AT AT93905896T patent/ATE193290T1/de not_active IP Right Cessation
- 1993-02-11 DK DK93905896T patent/DK0626969T3/da active
- 1993-02-11 WO PCT/US1993/001247 patent/WO1993016674A1/en active Application Filing
- 1993-02-11 CA CA002129897A patent/CA2129897C/en not_active Expired - Fee Related
- 1993-02-11 DE DE69328716T patent/DE69328716T2/de not_active Expired - Fee Related
- 1993-02-11 JP JP51489693A patent/JP2001527506A/ja not_active Ceased
- 1993-02-11 ES ES93905896T patent/ES2149201T3/es not_active Expired - Lifetime
- 1993-02-11 PT PT93905896T patent/PT626969E/pt unknown
- 1993-02-11 AU AU36645/93A patent/AU3664593A/en not_active Abandoned
- 1993-02-11 KR KR1019940702793A patent/KR100291112B1/ko not_active IP Right Cessation
- 1993-02-11 EP EP93905896A patent/EP0626969B1/en not_active Expired - Lifetime
- 1993-08-06 US US08/102,877 patent/US5648373A/en not_active Expired - Fee Related
- 1993-11-02 KR KR1020007011694A patent/KR100365913B1/ko not_active IP Right Cessation
1997
- 1997-10-17 AU AU41867/97A patent/AU701541B2/en not_active Ceased
1998
- 1998-12-22 HK HK98114789A patent/HK1013421A1/xx not_active IP Right Cessation
2000
- 2000-07-27 GR GR20000401730T patent/GR3034040T3/el not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE69328716T2 (de)	2000-11-23
PT626969E (pt)	2000-11-30
CA2129897A1 (en)	1993-08-12
KR100365913B1 (ko)	2002-12-26
HK1013421A1 (en)	1999-08-27
ATE193290T1 (de)	2000-06-15
DK0626969T3 (da)	2000-10-30
US5648373A (en)	1997-07-15
AU6482698A (en)	1998-07-16
EP0626969A4 (en)	1995-04-19
ES2149201T3 (es)	2000-11-01
GR3034040T3 (en)	2000-11-30
AU703236B2 (en)	1999-03-18
KR100291112B1 (ko)	2001-09-17
AU4186797A (en)	1998-01-08
CA2129897C (en)	2006-01-10
DE69328716D1 (de)	2000-06-29
EP0626969A1 (en)	1994-12-07
WO1993016674A1 (en)	1993-09-02
AU3664593A (en)	1993-09-13
EP0626969B1 (en)	2000-05-24
AU701541B2 (en)	1999-01-28
JP2001527506A (ja)	2001-12-25

Legal Events

Date	Code	Title	Description
1998-02-05	A201	Request for examination
1999-12-20	E902	Notification of reason for refusal
2000-05-20	AMND	Amendment
2000-09-22	E601	Decision to refuse application
2000-10-20	A107	Divisional application of patent
2000-10-20	J201	Request for trial against refusal decision
2000-12-28	B701	Decision to grant
2001-03-08	GRNT	Written decision to grant
2005-01-13	FPAY	Annual fee payment	Payment date: 20050114 Year of fee payment: 5
2006-03-09	LAPS	Lapse due to unpaid annual fee

Publication	Publication Date	Title
KR950700734A (ko)	1995-02-20	코엔자임 에이-독립성 트랜스아실라제 및 혈소판 활성화인자 억제제(CoA-IT and PAF inhibitors)
HUP9902103A2 (hu)	1999-10-28	Triarilvegyületek
DK1030836T3 (da)	2003-05-26	Hydroxam- og carboxylsyrederivater der har MMP- og TNF-inhiberende aktivitet
FI971412A (fi)	1997-04-04	Peptididyyliyhdisteet ja niiden terapeuttinen käyttö metalloproteaasien estäjinä
HUP0400689A2 (hu)	2004-06-28	ABCA-1 szint-emelő vegyületek
TR199801151T2 (xx)	1998-08-21	Trombin inhibit�r� �n ila�lar.
DE69531864D1 (de)	2003-11-06	Indolizin spal2 inhibitoren
DK1119362T3 (da)	2006-06-12	Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion
TR200102399T2 (tr)	2002-01-21	Tiyoamid türevleri
TR200401545T4 (tr)	2004-08-23	NOSS inhibitörü ilaçların amalatı için ikame imidazo [1,2-a]piridin-,-pirimidin- ve-pirazin-3-amin-türevlerinin kullanımı
DE69330459T2 (de)	2002-05-29	Verbindungen zur behandlung von allergischen und entzündlichen erkrankungen
ATE215366T1 (de)	2002-04-15	3-benzoylphenylessigsäure-derivate enthaltende topische zusammensetzungen zur behandlung der ophthalmischen entzündungserkrankungen
FI935675A0 (fi)	1993-12-16	Pyrazolopyrimidiner
GB0025670D0 (en)	2000-12-06	Preparation for the relief of inflammatory disease
ATE218336T1 (de)	2002-06-15	Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
ATE284860T1 (de)	2005-01-15	Neue verwendung von phenylheteroalkylamin- derivaten
DE69935720D1 (de)	2007-05-16	Diamino-propanol-verbindungen zur behandlung von ischaemien
NO983992L (no)	1998-10-30	Serinprotease inhibitorer
DK0782441T3 (da)	2003-06-30	Farmaceutisk kontrol af inflammation
DK1305037T3 (da)	2007-09-17	Smertestillende medikament
ATE203905T1 (de)	2001-08-15	Thrombin inhibitor
ES2056983T3 (es)	1994-10-16	Compuestos para inhibir la biosintesis de metabolitos de acido araquidonico derivados de lipoxigenasa.
FR2395998A1 (fr)	1979-01-26	Nouveaux derives de la thiazolidine et leur application dans le traitement de l'hypertension
DK0633776T3 (da)	2001-08-27	Forbindelser, som kan anvendes til behandling af allergiske og inflammatoriske sygdomme
DE60103035D1 (de)	2004-06-03	Neue verwendung von phenylheteroalkylamin-derivaten